Table 4 Patient outcomes
From: Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma
Patient No. | Disease Response | Time to Progression (m; from infusion) | Survival (m) | Outcome | |
|---|---|---|---|---|---|
From diagnosis | From infusion | ||||
01 | PD | 4 | 12 | 6 | DOD |
02 | PD | 2 | 26 | 7 | DOD |
03 | SD | No progression | 11 | 4 | Dead from brain herniation |
04 | PR | No progression | 35 | 24 | Alive |
05 | PD | 7 | 29 | 23 | Alive |
06 | PR | No progression | 23 | 12 | Alive |
07 | PR | No progression | 15 | 13 | Alive |
08 | PR | No progression | 7 | 3 | Alive |